BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Healthtrust
Fish and Richardson
UBS
Chinese Patent Office
Boehringer Ingelheim
Federal Trade Commission
Citi
Chubb

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040394

« Back to Dashboard

NDA 040394 describes BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, which is a drug marketed by Graham Dm, Hikma Pharms, Mallinckrodt, Mayne Pharma Inc, Nexgen Pharma, Nuvo Pharm Inc, Tedor Pharma Inc, Mikart, Able, Actavis Labs Ut Inc, Cnty Line Pharms, Gilbert Labs, Lannett Holdings Inc, Mallinckrodt Inc, Mirror Pharms Llc, Novast Labs Ltd, Sun Pharm Industries, Vintage Pharms, and Watson Labs, and is included in twenty-eight NDAs. It is available from forty-nine suppliers. Additional details are available on the BUTALBITAL, ACETAMINOPHEN AND CAFFEINE profile page.

The generic ingredient in BUTALBITAL, ACETAMINOPHEN AND CAFFEINE is acetaminophen; butalbital; caffeine. There are sixty-six drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the acetaminophen; butalbital; caffeine profile page.
Summary for 040394
Tradename:BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Applicant:Able
Ingredient:acetaminophen; butalbital; caffeine
Patents:0
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength500MG;50MG;40MG
Approval Date:Jul 23, 2001TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
Merck
Cantor Fitzgerald
Deloitte
Daiichi Sankyo
Moodys
Harvard Business School
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot